Back grey_arrow_rt.gif
Study explains why HIV so tough to beat, gp41 HIV Antibodies/Vaccine Research - published article in Nature journal below
  Updated Tue Nov 16, 2010 12:02am AEDT
· Audio: Scientists discover HIV's success (PM)
· Map: Melbourne 3000
Scientists have solved one of the great mysteries of the HIV/AIDS virus: why it is so successful at breaking down the body's resistance.
A paper in the journal Nature, published today, lays out the reasons why humans do not produce antibodies against the virus.
This lack of a natural defence allows the virus to enter cells without being attacked.
The findings offer new hope for vaccines which could target HIV/AIDS more effectively.
The key is a potential weak link, a protein on the surface of HIV called gp41, which helps the virus invade cells.
Professor Stephen Kent, an immunologist at the University of Melbourne, says gp41 has been of great interest to HIV vaccinologists.
"The GP41 component is the component that essentially punches a hole in the membrane or the surface of the cell and allows the virus to get in," he said. "It's a very critical component of the entry mechanism of the virus.
"If we can prevent the HIV from getting into cells, then we'd have a great vaccine."
It has been known for many years that about one in 1,000 people can naturally control the HIV virus, by making an antibody against gp41.
The work published in Nature shows that while most people do develop an antibody against gp41, they do this after the virus has already entered their cells. "They're making a response against this gp41 after the horse has already bolted," Professor Kent said.
"And so the virus gets in, it infects, it destroys these CD4 cells, and only then is the antibody made.
"It's disappointing, but at the same time it's also a clue. As we understand this better we can now try and direct our efforts against the specific parts of gp41 that we can attack before the virus can get into the cell.
"It's perhaps a couple of steps back and one step forward for HIV vaccine research."
Distinct conformational states of HIV-1 gp41 are recognized by neutralizing and non-neutralizing antibodies - pdf attached
Download the PDF here
Nature Structural & Molecular Biology Nov 16 2010
Gary Frey, Jia Chen,Sophia Rits-Volloch,Michael M Freeman,Susan Zolla-Pazner. Bing
HIV-1 envelope glycoprotein gp41 undergoes large conformational changes to drive fusion of viral and target cell membranes, adopting at least three distinct conformations during the viral entry process. Neutralizing antibodies against gp41 block HIV-1 infection by targeting gp41's membrane-proximal external region in a fusion-intermediate state. Here we report biochemical and structural evidence that non-neutralizing antibodies, capable of binding with high affinity to an immunodominant segment adjacent to the neutralizing epitopes in the membrane-proximal region, recognize a gp41 conformation that exists only when membrane fusion is complete. We propose that these non-neutralizing antibodies are induced in HIV-1-infected individuals by gp41 in a triggered, postfusion form and contribute to production of ineffective humoral responses. These results have important implications for gp41-based vaccine design.
The first crucial step of HIV-1 infection is fusion of viral and target cell membranes. Viral attachment and membrane fusion are mediated by viral-envelope glycoprotein upon engagement with cellular receptors1, 2. The envelope protein is synthesized as a precursor, gp160, which trimerizes and undergoes cleavage into two noncovalently associated fragments, the receptor-binding fragment gp120 and the fusion fragment gp41 (refs. 3,4). Three copies of each fragment make up the mature viral spike, which constitutes the sole antigen on the virion surface. Sequential binding of gp120 to the primary receptor CD4 and coreceptor (for example, CCR5 and CXCR4) induces large conformational changes, which then trigger dissociation of gp120 and a cascade of refolding events in gp41 (refs. 1,5). gp41, with its C-terminal transmembrane segment inserted in the viral membrane, is folded into a prefusion conformation within the precursor, gp160. Cleavage between gp120 and gp41 makes this prefusion conformation metastable with respect to a rearranged, postfusion conformation. When triggered by the binding of gp120 to the coreceptor, the N-terminal fusion peptide of gp41 translocates and inserts into the target cell membrane. The extended conformation of the protein, with the fusion peptide inserted into the cell membrane and the transmembrane anchor in the viral membrane, is referred to as the 'prehairpin intermediate'6. It can be targeted by T20 (Enfuvirtide), the first approved fusion-inhibiting antiviral drug, as well as by certain broadly neutralizing antibodies7, 8, 9. Subsequent rearrangements involve folding back of the C-terminal heptad repeat 2 (HR2) region of gp41 into a hairpin conformation, creating a six-helix bundle, which places the fusion peptide and the transmembrane segment at the same end of the molecule10, 11. This irreversible refolding of gp41 effectively brings the two membranes together. During the fusion process, gp41 adopts at least three distinct conformational states: the prefusion conformation; an extended, prehairpin intermediate; and the postfusion conformation. The conformational differences among these states are so great that each of them probably presents distinct antigenic surfaces to the immune system.
HIV-1-infected people typically generate strong antibody responses to the envelope glycoprotein, but most of these antibodies are either non-neutralizing or strain-specific, and many recognize epitopes occluded on mature trimeric spikes or epitopes located in the highly variable loops. Extensive glycosylation, sequence diversity, and receptor-triggered conformational changes and epitope masking pose great challenges to generation of broadly reactive neutralizing antibodies12, 13, 14. Some sera from infected individuals show broadly neutralizing activity, but immunogens that can induce such antibody responses have remained elusive15. Nevertheless, a number of broadly reactive neutralizing monoclonal antibodies (mAbs) have been isolated that recognize regions of the HIV-1 envelope glycoprotein. Some are located on gp120: the CD4 binding site, the V2 and V3 loops and the carbohydrates on the outer domain of gp120 (refs. 16,17,18,19,20,21,22). Additional neutralizing antibodies target a region on gp41 adjacent to the viral membrane, called the membrane-proximal external region (MPER; residues 662-683 (HXB2 numbering))23, 24, 25. Our previous studies on the molecular mechanism of neutralization by two of these gp41 antibodies, 2F5 and 4E10, indicate that their epitopes are exposed or formed only on the prehairpin-intermediate state during viral entry9. We also have found that the hydrophobic CDR H3 loops of these antibodies mediate a reversible attachment to the viral membrane that is essential for their antiviral activities26. These MPER-directed antibodies probably associate with the viral membrane in a required first step and are poised to capture the transient gp41 fusion intermediate9, 26.
gp41 also induces non-neutralizing antibodies, which are much more abundant in infected individuals than neutralizing ones. The non-neutralizing antibodies have been classified into two groups according to the location of their epitopes. Cluster I antibodies react with the immunodominant C-C loop of gp41 (residues 590-600), and cluster II antibodies recognize another immunodominant segment (residues 644-663) next to the MPER27. Members in the latter group can bind HIV-1 gp41 with high affinity but have weak or no neutralizing or antiviral activities28, 29. The prototype of this group includes mAbs 98-6, 126-6, 167-D, 1281 and 1379, isolated by immortalizing plasma B cells from HIV-1-positive people27, 30, 31, 32. These mAbs seem to react optimally with gp41 in its postfusion conformation33, but they also bind 'monomeric gp41' (probably aggregated protein, as monomeric gp41 is not stable) and oligomer-specific conformations of gp41 (refs. 31,34). As the conformation of these envelope preparations has not been fully assessed, it remains uncertain which conformation(s) of gp41 the cluster II mAbs recognize and why they are incapable of blocking HIV-1 infection.
Here we set out to investigate the structural basis for the drastic differences between the MPER-directed antibodies and the cluster II antibodies in their ability to neutralize HIV-1 infection. We have produced an improved gp41 construct to mimic its prehairpin-intermediate conformation. This protein binds tightly to broadly neutralizing antibodies 2F5, 4E10 and Z13e1 (ref. 35). We present biochemical and structural data to demonstrate that cluster II antibodies to HIV-1 gp41 show high binding affinity for the postfusion conformation of gp41 and do not bind or bind only weakly to the stable, homogeneous gp41 preparations representing the prehairpin intermediate or the prefusion conformation. We propose that these antibodies are non-neutralizing because they target a late step in the viral entry process, when membrane fusion is likely to be complete.
Production of GCN4-gp41-inter

In our previous studies, we have produced homogeneous preparations of trimeric HIV-1 envelope protein, derived from a clade A isolate, 92UG037.8, to mimic its prefusion (gp140), prehairpin intermediate (gp41-inter) and postfusion (gp41-post) conformations (Fig. 1)9. We have demonstrated that the different conformational states of gp41 have markedly different antigenic characteristics. In particular, two MPER-directed neutralizing antibodies, 2F5 and 4E10, inhibit HIV-1 infection by targeting the prehairpin-intermediate state of gp41 (refs. 9,26). To define the conformational state recognized by anti-gp41 cluster II antibodies, we sought to test their reactivity to gp140, gp41-inter and gp41-post. gp41-inter was designed to capture gp41 in the extended, prehairpin-intermediate conformation with the following sequence: (HR2)-linker-(HR1-C-C loop-HR2-MPER)-(trimerization foldon tag) (Fig. 1). This construct can be pictured as the prehairpin intermediate captured by a covalently linked HR2 peptide, such as T20. When gp41-inter chains trimerize, the N-terminal HR2 segments (T20) form a six-helix bundle with the HR1 segments, whereas the C-terminal HR2 segments, constrained by the foldon tag, are unable to form a six-helix bundle. Thus, the two copies of HR2 in gp41-inter are in distinct conformations: the N-terminal HR2 is in the six-helix, postfusion state, and the C-terminal HR2 mimics the prehairpin intermediate. Using gp41-inter as a reagent to analyze antibodies directed against HR2, such as cluster II mAbs, would complicate data interpretation. We therefore designed a modified gp41-inter in which the entire six-helix bundle (the segment HR2-linker-HR1) was replaced with a trimeric GCN4-derived coiled coil to generate GCN4-gp41-inter (Fig. 1)36. The heptad repeat of GCN4 needed to be in the same register as the HR1 region of gp41 to avoid any structural distortion. GCN4-gp41-inter was expressed in Escherichia coli and refolded in vitro with the same protocol we developed for gp41-inter (see ref. 9 and Online Methods). As expected, purified GCN4-gp41-inter is also a monodisperse trimer and is stable after several rounds of gel-filtration chromatography (Supplementary Fig. 1).
To confirm that replacement of the six-helix bundle with GCN4 does not alter antigenic properties of gp41-inter, we carried out binding experiments using surface plasmon resonance (SPR) to assess reactivity of GCN4-gp41-inter to three MPER-directed mAbs, 2F5, 4E10 and Z13e1. Both gp41-inter and GCN4-gp41-inter proteins showed the same kinetic profile for binding to the antibodies (Supplementary Fig. 2 and Supplementary Table 1), indicating that the conformation of MPER is identical in the two constructs. We note that Z13e1, the least potent neutralizing antibody among the three, dissociated from gp41 much more rapidly that did 2F5 and 4E10, consistent with our earlier suggestion that a slow dissociation rate of antibody-gp41 complex may be crucial for the neutralizing activity of MPER-directed antibodies26. The interactions of gp41 with the three antibodies fit well to the 1:1 Langmuir binding model (Supplementary Fig. 2). Moreover, both gp41-inter and GCN4-gp41-inter formed tight complexes with cluster I antibodies, such as 240-D and 246-D27, which we were able to purify by gel-filtration chromatography (data not shown), suggesting that substitution of the six-helix bundle in gp41-inter with GCN4 does not introduce any structural distortion. We conclude that GCN4-gp41-inter is trapped in the same fusion-intermediate conformation as is gp41-inter.
Cluster II mAbs recognize the postfusion state of gp41
To assess binding specificity of cluster II antibodies, we chose a panel of five human mAbs, including 98-6, 126-6, 167-D, 1281 and 1379 (refs. 27,30,31), and tested their reactivity to gp140, GCN4-gp41-inter and gp41-post by SPR. All the antibodies have previously been shown by ELISA to bind a full-length recombinant gp41 and oligomeric gp140, as well as a six-helix bundle formed by HR1 and HR2 peptides; 98-6 is the only one that reacts with an HR2 peptide alone31, 33. All the antibodies showed tight binding to the postfusion conformation of gp41, with extremely fast on-rates (Fig. 2 and Supplementary Fig. 3), in agreement with the previous findings33, indicating that the six-helix bundle presents the optimal conformation recognized by these antibodies. In contrast, none of the antibodies showed any binding to GCN4-gp41-inter, which does contain the cluster II epitopes (residues 644-663), suggesting the residues in gp41 crucial for interacting with cluster II antibodies are either buried or not correctly configured for antibody recognition in the prehairpin-intermediate state. In particular, mAb 98-6, capable of forming a complex with an unconstrained and flexible HR2 peptide, did not show any detectable binding to GCN4-gp41-inter, further confirming that gp41-inter presents a unique conformation that is incompatible with recognition by the non-neutralizing cluster II antibodies. Our stringently characterized gp140 trimer showed only weak binding to four of these mAbs and no binding at all to mAb 1379 (Fig. 2 and Supplementary Fig. 3). Moreover, all the cluster II antibodies showed barely detectable binding to the same envelope trimer expressed on 293T cell surfaces, as did 2F5, which does not recognize the native, prefusion conformation of gp41 (Supplementary Fig. 4). Together, these results indicate the non-neutralizing HIV-1 gp41 cluster II antibodies recognize only the postfusion conformational state of gp41, which is distinct from the fusion-intermediate conformation targeted by the MPER-directed broadly neutralizing antibodies.
Interaction of gp41-post with the monovalent 1281 Fab
Although bivalent IgG is the physiologically relevant form, intrinsic affinity of its antigen-combining site to target antigens could be masked by avidity effects. To gain further insights into how cluster II antibodies interact with gp41 in its postfusion conformation, we chose mAb 1281 as a representative and produced the Fab fragment to eliminate avidity effects. The 1281 Fab showed the same pattern for binding to the envelope proteins: high affinity to gp41-post, weak affinity to gp140 and no binding to GCN4-gp41-inter (Fig. 3a), fully consistent with our results using the intact IgG. Additionally, the Fab did not interact with GCN4-gp41-inter at a wide range of concentrations (1-100 nM; Fig. 3b), further confirming the notion that HR2 adopts a conformation in the prehairpin intermediate that is completely different from the six-helix-bundle conformation. We predicted that gp41-inter with the N-terminal HR2 folding back on the HR1 to form a six-helix bundle would bind the 1281 Fab the same way as does gp41-post. Indeed, the kinetic properties of the Fab binding to gp41-inter and gp41-post were almost identical (Fig. 3c,d). We note that the kinetic characteristics of 1281 Fab binding to gp41-post were not very different from those of Z13e1 binding to gp41-inter, suggesting that affinity of an antibody to gp41 alone is not an indicator of its antiviral activity.
Crystal structure of the 1281 Fab-gp41-post complex
To obtain a structural definition of the cluster II epitopes, we determined the crystal structure of the complex of gp41-post and 1281 Fab at 3.3-Å resolution. Crystals of the 1281 Fab-gp41-post complex diffract to 3.3-Å resolution and belong to space group R3, with one Fab and one gp41 monomer per crystallographic asymmetric unit. The structure was determined by molecular replacement using HIV-1 gp41 monomer (PDB 1AIK)10 and a library of Fab coordinates as search models37. Searches for gp41 and Fab yielded convincing solutions. The constant region of 1281 Fab shares 100% sequence identity with that of the search model, and thus the two should have the same structure. However, density for the constant region remained poor throughout the rebuilding and refinement process (Supplementary Fig. 5a,b), indicating there is some packing disorder in this domain. The variable region together with gp41 could form a complete lattice in the absence of the constant domain, which may therefore have more than one orientation in the crystal (Supplementary Fig. 5c). Complementarity-determining regions (CDRs) of both heavy and light chains of 1281 were rebuilt iteratively, and the final model was refined with an Rwork of 26.1% and an Rfree of 28.9% (Table 1).
As expected, gp41-post derived from the clade A isolate 92UG037.8 forms a six-helix bundle similar to the structures of gp41 determined for HIV-1 clade B isolates and simian immunodeficiency viruses10, 11, 38, 39. The 2F5 epitope in the MPER of gp41-post adopts an α-helical conformation (Fig. 4) distinct from that in the crystal structure of the 2F5-gp41 peptide complex, in which the epitope stretches into an extended conformation with two overlapping type I ß-turns40. The CDR loops from both the heavy and light chains of 1281 Fab interact extensively with the six-helix bundle. The CDR H1 and L2 loops contact the HR2 helix in gp41-post exclusively, whereas the CDR H3 interacts with both the HR1 and HR2 helices (Fig. 4). Two segments (residues 97-100 and 100C-100E) of CDR H3 pack against residues 560-564 in HR1 (Fig. 5a). The footprint of the antibody covers residues 643-661 of HR2 (Fig. 5b), fully consistent with previous epitope-mapping data27, 33, 34. The observation that 1281 Fab makes direct contacts with the HR1 helix is in agreement with the previous findings that most cluster II antibodies interact with the six-helix bundle, but not with HR1 or HR2 peptide alone33. Binding of 1281 Fab does not induce major structural rearrangements in gp41, as judged by comparison of gp41-post with the other six-helix-bundle structures10, 11. The distance between the centers of the 2F5 and 1281 epitopes is ∼30 Å, confirming their spatial closeness (Figs. 4 and 5).
Developing a safe and effective vaccine that durably blocks HIV-1 infection is one of the highest priorities for global health. Conventional strategies based on empirical approaches have failed to provide adequate protection against HIV-1 infection in clinical trials41, 42. Innovative approaches are urgently needed. The HIV-1 envelope glycoprotein has evolved to undergo large structural rearrangements with very different conformational states during viral entry, and each state has distinct antigenic characteristics. Rational design of an effective envelope-based immunogen will probably require a deeper understanding of the structural correlates of envelope antigenicity and immunogenicity. We sought to study the structural basis for the drastic differences between the MPER-directed antibodies and the cluster II antibodies in their ability to neutralize HIV-1 infection, despite their equivalently high affinity for HIV-1 gp41. We have previously reported that the broadly neutralizing mAbs 4E10 and 2F5 do not bind the prefusion form of gp41, but rather target only the prehairpin-intermediate conformation9. gp41-inter, a gp41 designed to mimic the prehairpin intermediate, was instrumental in that study. 4E10 and 2F5 bind almost irreversibly to gp41-inter, whereas their complexes with the soluble peptide epitopes dissociate much more rapidly9, consistent with the notion that the very slow dissociation rate of the antibody-gp41 complex may be crucial for targeting a fusion intermediate, as dissociation could allow gp41 to proceed toward fusion. Moreover, addition of gp41-inter was able to efficiently block neutralization by 4E10 even when the antibody was preincubated with the virus26, whereas the 4E10 epitope peptide was ineffective under the same setting (M. Alam and B.C., unpublished data), suggesting that gp41-inter is in a conformation relevant to both membrane fusion and antibody neutralization. To examine the conformational specificity of the cluster II mAbs, it was necessary to modify our original gp41-inter design by replacing the postfusion component with an unrelated trimeric GCN4 (Fig. 1)9. Here we show that HIV-1 gp41 cluster II antibodies, which recognize a segment adjacent to the neutralizing epitopes in the MPER, have high affinity only for gp41 in the postfusion conformation. These antibodies are ineffective in preventing HIV-1 infection as they target a late step in the viral entry process, when membrane fusion is likely to be complete. We propose that the stable postfusion conformation of gp41 probably serves as a decoy to help HIV-1 evade the immune system and induce ineffective antibody responses in infected people. Rational design of gp41-based immunogens would require strategies to constrain gp41 and prevent it from folding into the six-helix-bundle conformation.
Neutralizing antibodies against gp41 are rare, whereas gp41-specific non-neutralizing antibodies are often very abundant27. Cluster I antibodies directed at the C-C loop are not neutralizing, either because these epitopes are not readily accessible on the functional envelope trimer or because antibody binding to the C-C loop does not impede the envelope function28, 43, 44. The question of why cluster II antibodies are non-neutralizing has been puzzling, however, especially because their epitopes are near the broadly neutralizing epitopes in the MPER. Our previous studies on the neutralization mechanism by MPER-directed mAbs have shown that 4E10 and 2F5 target the gp41 prehairpin intermediate9, 26. Furthermore, the ability of these antibodies to interact with the HIV-1 membrane is crucial for them to capture their MPER target presented in the transient intermediate state45, 46. Thus, it appears that the neutralizing activity of a gp41 antibody correlates with its capacity to bind viral membrane and gp41 in the fusion-intermediate conformation. Some cluster II mAbs, including 126-6, 167-D and 1281, can also interact with membrane lipids (M. Alam and B.F. Haynes, Duke University, personal communication). In addition, the cluster II epitopes are more membrane-distal than the MPER, and these mAbs would need a much longer hydrophobic CDR loop to bind both gp41 and the membrane simultaneously. Thus, membrane-binding properties are unlikely to be the reason why the cluster II mAbs are not neutralizing. Our results demonstrate that the postfusion conformation of gp41 is the high-affinity target of the cluster II antibodies. The only two opportunities when this conformational state of gp41 is accessible to antibodies during viral entry are when gp120 dissociates prematurely (gp120 shedding) to leave nonfunctional gp41 'stumps' on the surface of virion47, and when membrane fusion is complete. In both cases, binding by cluster II mAbs would not obstruct the function of gp41 and thus would have no impact on HIV-1 entry.
Cluster II antibodies could mediate HIV-1-specific antibody-dependent cellular cytotoxicity (ADCC) and other Fc-mediated antiviral activities29, 48, 49, 50. Our data indicate that these antibodies bind with high affinity only to the triggered form of gp41 on the surface of the virion, and not to the native envelope spikes. For any given HIV-1 envelope, ADCC that targets the cluster II epitopes would have to depend on how much gp120 sheds spontaneously and how many nonfunctional gp41 stumps are present on the viral membrane surface. Thus, cluster II mAb-mediated ADCC would be more effective against isolates that shed gp120 readily, whereas those with the much more stable (gp120-gp41)3 complex would be more resistant.
Cluster II epitopes are very immunogenic in vivo27 and could help HIV-1 evade the immune system by triggering production of non-neutralizing antibody responses. A recent study that cloned HIV antibodies against HIV-1 gp41 from the memory B-cell compartment of HIV-1-infected individuals has shown that unique B-cell clones targeting cluster II epitopes account for 49% of all anti-gp41-reactive B cells51. The crystal structure of 1281 Fab in complex with gp41-post shows that the antibody makes direct contacts with both HR1 and HR2, suggesting that the six-helix bundle is probably the immunogen that induces this type of antibody response in HIV-1-infected people. The gp120-depleted gp41 stumps, which do interact with cluster II antibodies47, observed on the surface of virion are probably in the triggered, six-helix-bundle form and may be the chief source of gp41 immunogens responsible for this type of antibody response. HIV-1 may thereby exploit the envelope stability as one of its immune-evasion tactics to distract the immune system from the native, functional trimers.
HIV-1 envelope-based immunogens often induce high-ELISA-titer antibody responses with limited neutralizing activity or breadth. Most envelope immunogens containing gp41 have not been rigorously characterized, particularly with respect to their conformational homogeneity. For example, HIV-1 gp140 preparations are often a mixture of monomers, dimers, trimers and aggregates, and it is difficult to discern what conformation each of these species represents and whether they are physiologically relevant. gp41 could adopt the most stable, postfusion conformation in some of these irrelevant forms and expose immunodominant, non-neutralizing epitopes, such as those recognized by the cluster II antibodies. These preparations could lead to misinterpretation of the antigenic and immunogenic properties of the envelope protein and hence misguide efforts toward immunogen design. Another important and understudied aspect of protein-based immunogen design is the potential impact that adjuvant formulation may have on immunogen structure. For instance, emulsions using oil-based adjuvants could potentially disrupt protein structural integrity and trigger conformational changes in gp41. Empirical approaches to develop gp41-based immunogens that overlook these structural details of immunogens might primarily induce non-neutralizing antibody responses. For a genuinely rational immunogen design, steps must be taken to prevent gp41 from folding into the postfusion conformation.
Expression and refolding of gp41 proteins.
Antibody and Fab production.

The human cluster II monoclonal antibodies to HIV-1 gp41, 98-6, 126-6, 167-D, 1281 and 1379, were produced as described27, 30, 31. Fab fragments of 2F5, 4E10 and Z13e1 were expressed in insect cells and purified by GammaBind Plus Sepharose beads (GE Healthcare). Recombinant baculoviruses containing the heavy chain or the light chain of Fab were generated separately and mixed at a volume ratio of 1:1. Typically, 12 l of Sf9 cells were infected with recombinant baculoviruses at a multiplicity of infection of 2.5. The cell supernatants were harvested 72 h after infection by centrifugation, concentrated and loaded onto a GammaBind Plus Sepharose column. Bound Fab was eluted by 100 mM glycine (pH 2.5) and further purified by gel-filtration chromatography on a Superdex 200 (GE Healthcare). The Fab fragment of mAb 1281 was produced by papain (Sigma) digestion at 37 °C for 4 h with an enzyme-to-antibody ratio of 1:1,000 by weight, and then purified by Protein A affinity and gel-filtration chromatography.
SPR binding assays.
All experiments were performed in duplicate with a Biacore 3000 instrument at 20 °C, with immobilization levels between 300 and 400 response units (RU) to avoid rebinding events. The experiments were run with a flow rate of 50 µl min-1, with a 2-min association phase and a 10-min dissociation phase. HBS-EP (10 mM HEPES pH 7.4, 150 mM NaCl, 3 mM EDTA) was the running buffer for experiments using CM5 chips; and a buffer containing 10 mM HEPES pH 7.4, 150 mM NaCl, 50 µM EDTA and 0.005% (v/v) P20 was the running buffer for those using Ni-NTA chips.
Binding of 2F5, 4E10 or Z13e1 Fab to GCN4-gp41-inter and gp41-inter were performed as follows. GCN4-gp41-inter or gp41-inter was coupled to a CM5 chip at ∼300-400 RU for 2F5 and 4E10 binding and at ∼100 RU for Z13e1 binding using a standard amine coupling procedure. Sensorgrams were recorded by passing each Fab at various concentrations over the ligand surface. The surface was regenerated between each experiment by a single injection (3 s) of 35 mM NaOH and 1.3 M NaCl at a flow rate of 100 µl min-1. 1281 Fab and cluster II IgG's binding to gp41-post and GCN4-gp41-inter were performed with gp41-post or GCN4-gp41-inter immobilized to a CM5 chip as described above. The chip surface was regenerated between each experiment using a single injection (3 s) of 35 mM NaOH and 1.3 M NaCl at a flow rate of 100 µl min-1. Binding of 1281 Fab to the gp140 trimer was done by capturing the His-tagged gp140 on a Ni-NTA chip, and 1281 Fab at various concentrations was passed over the chip surface. The surface was regenerated between each experiment with 10 mM HEPES pH 8.3, 150 mM NaCl, 350 mM EDTA and 0.005% (v/v) P20. To avoid potential artifacts introduced by protein immobilization to a CM5 chip, Protein A was first immobilized to a CM5 chip at ∼1,000 RU using the standard procedure. Each IgG was then captured to the Protein A surface at ∼400 RU. Each of gp140, GCN4-gp41-inter or gp41-post at 50 nM was passed over each antibody surface individually. The surface was regenerated using 10 mM HCl. Binding kinetics were analyzed by BiaEvaluation software (Biacore) using a 1:1 Langmuir binding model. All injections were carried out in duplicate, and duplicates gave essentially identical results.
Crystallization and structure determination.
Crystals of the complex of gp41-post and 1281 Fab were obtained using the hanging-drop vapor diffusion method. Briefly, 1 µl of protein solution (15 mg ml-1) was mixed with 1 µl of mother liquor (0.1 M Tris-HCl, 15% (w/v) PEG 4K) and allowed to equilibrate at 25 °C. Crystals were flash-frozen in liquid N2 using 20% (v/v) glycerol in the mother liquor as a cryoprotectant. X-ray diffraction data were collected at 100 K at beamline 24-ID, Advanced Photon Source (Argonne National Laboratory). The best crystals diffracted to a Bragg spacing of 3.3 Å with space group R3 (a = 115.8, b = 115.8, c = 119.53). Initial phases were obtained by molecular replacement using the ectodomain of gp41 as a search model10. The top solution of this search was fixed, and a second search against a library of 244 antibody fragment structures was performed using MOLREP and Phaser37, 52, 53, yielding a single solution. The three-fold axis of the gp41 trimer coincides with the crystallographic three-fold, and there are one monomer of gp41 and one Fab in an asymmetric unit. Mild anisotropy in the data was observed and subsequently corrected using a diffraction anisotropy server before refinement54. Electron density for the constant domain of the Fab fragment was poor. A complete lattice can form via the variable region of Fab and gp41 in the absence of the constant domain, suggesting that this domain may have more than one orientation in the lattice. The R factors were ∼32% when the constant region was excluded for refinement. Model-building was performed iteratively in O and Coot, and refinement in Phenix and Refmac55, 56, 57, 58. The final model was refined with an Rwork of 26.1% and an Rfree of 28.9%. As analyzed by Procheck59, 89.7% of residues are in most favored regions of the Ramachandran plot, 8.9% in additional allowed regions, 1.3% in generously allowed regions and none in disallowed regions. All the structure figures were made in PyMOL60.
  icon paper stack View Older Articles   Back to Top